Fairooz Kabbinavar: Yes, so, Andy, just building up on what Mark just said, in the Phase 1b/2 trial we looked at multiple other factors trying to see were there any other features that would impact these responses that we’re seeing in bev naïve patients. And to give you a very short answer, absolutely no clinical feature appeared to play a role in significant robust responses that were seen in the bev naïve patients. So, we looked at laterality of the tumors, right and left tumors, both responded equally. We looked at patients with liver met, without liver met, they all seem to respond well. We looked at patients who had gender did not impact the outcome. So, we think that this point, based on what we have seen in the Phase 1b/2 trial and that if the bev naivety, if you will, that there is a significant role in the dramatic synergy that you’re seeing between bev and onvansertib plus chemotherapies.
Andy Hsieh: I see. That’s very helpful. So, maybe moving out of the — sorry, actually before we move on, so in terms of managing neutropenia for the ongoing 004 study, are you considering doing growth factor prophylaxis for patients?
Fairooz Kabbinavar: Well, the three things that we normally would use, hold the dose or delay the next dose, allow the bone marrow to recover. If it doesn’t recover, then we use growth factors according to ASCO guidelines. And then, subsequently, I mean, we also have the option of doing dose reduction depending on which drug is the culprit. But again, going back to 1/b2 trial and others, we have not found a reason for us to dose decrease. So, we have all the options that will standard of — that we would normally use in managing these patients. But at this point, we don’t think it’s going to be a big issue.
Andy Hsieh: Got it. That’s helpful. And then, so outside of CRC, I believe small cell lung cancer in the September update was 1 PR3, stable disease patients. Do you have any updates on that cohort or that’s kind of the latest data?
Mark Erlander: I can say that we don’t have any updates. The PI has moved to another academic institution and so that has somewhat slowed down the accrual in that particular trial.
Andy Hsieh: I see. Great. Thank you so much for taking all of our questions and congratulations on the progress.
Mark Erlander: Thank you. Thank you, Andy.
Operator: Thank you. There are no further questions at this time. I’d like to turn the call back over to Jamie Levine for closing remarks. Thank you, Operator.
Jamie Levine: Thank you, Operator. This concludes our conference call and thanks again for joining us this afternoon. Bye-bye.
Operator: Thank you for your participation. This does conclude the program. You may now disconnect. Good day.
